HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol
Cheng Z, Li L, Zhang Y, Ren Y, Gu J, Wang X, Zhao H, Lu H. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol. Briefings In Bioinformatics 2023, 24: bbac601. PMID: 36736372, DOI: 10.1093/bib/bbac601.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaClinical stageImmune microenvironmentTumor sizeHepatitis B virus infectionLow alpha-fetoprotein levelsMetabolism-related proteinsRelevant subgroupsB virus infectionSevere liver dysfunctionGood liver functionHigh AFP levelsAlpha-fetoprotein levelsPrimary liver malignancySmaller tumor sizeLarger tumor sizeLower clinical stageHigher clinical stageCancer-related deathProliferation activityPrevention of HBVNear-normal levelsLow proliferation activityLiver dysfunctionHigh proliferation activityTargeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xie X, Yang Y, Wang Q, Liu H, Fang X, Li C, Jiang Y, Wang S, Zhao H, Miao J, Ding S, Liu X, Yao X, Yang W, Jiang J, Shao Z, Jin G, Bian X. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research 2023, 33: 215-228. PMID: 36627348, PMCID: PMC9977947, DOI: 10.1038/s41422-022-00766-z.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-L1Combination therapyTherapeutic responsePD-1/PD-L1 signalingShorter progression-free survivalBreast cancer benefitProgression-free survivalPD-L1 signalingCheckpoint inhibitorsNab-paclitaxelCancer benefitImmunotherapy cohortImmune microenvironmentPreclinical resultsTumor cell membranesTumor samplesPaclitaxelHigh expressionPromising targetPatientsTherapyTumorsResistant factorATAD3A expression